Press release
Soft Tissue Sarcoma Market to Witness Steady Growth During the Forecast Period 2017 – 2025
Soft tissues such as muscles, blood vessels, fat, tendons, and lining of the joints connect, support, and surround other body structures. Cancers that originate in these soft tissues are known as soft tissue sarcomas. There are more than 50 types of soft tissue sarcomas, including Kaposi sarcoma, Rhabdomyosarcoma, alveolar soft part sarcoma, adult fibrosarcoma, clear cell sarcoma, liposarcomas, and synovial sarcoma. Common types of soft tissue sarcomas include leiomyosarcoma, abdominal sarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma.
According to the American Cancer Society, more than 11,400 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. The causes of soft tissue sarcoma are difficult to determine; however, exposure to certain chemicals such as phenoxyacetic herbicides and dioxins; previous exposure to radiotherapy; old age; and certain genetic conditions are anticipated to increase the risk of soft tissue sarcoma. Diagnostic methods used to detect soft tissue sarcoma include PET scan, biopsy, CT scan, and X-ray imaging.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28250
Rise in incidence and prevalence of various types of soft tissue sarcomas, strong focus on research and development to enhance the treatment options available such as targeted therapies and biological therapies, large pipeline of drugs, growth in awareness among people, increase in approvals for the manufacture of generics, and rise in funding for research are some of the factors driving the market.
However, side effects associated with cancer treatment, high cost of treatment, stringent government regulations, and high failure rate in clinical trials are likely to hamper the soft tissue sarcoma market in the near future. Additionally, significant shortage of doxorubicin, one of the major drugs employed in chemotherapy, has been reported by the U.S. FDA. The lack of reimbursement for a majority of the registered drugs under the public insurance programs and the lack of availability of many of the oncology drugs in some of the regions might hamper the future market growth.
The soft tissue sarcoma market can be segmented based on treatment type, end-user, and geography. In terms of the type of treatment, the market can be divided into chemotherapy, targeted therapy, radiation therapy, and surgery. The chemotherapy treatment segment of the soft tissue sarcoma market generally involves a combination of various anti-cancer drugs.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=28250
Commonly used drugs include ifosfamide and doxorubicin. Other chemotherapy drugs include dacarbazine, cisplatin, oxaliplatin, paclitaxel, eribulin, and vincristine. Chemotherapy and targeted therapy segments are anticipated to dominate the soft tissue sarcoma market during the forecast period. In terms of end-user, the soft tissue sarcoma market can be classified into multi-specialty hospitals, cancer research centers, ambulatory surgical centers, and others. Multi-specialty hospitals are anticipated to remain dominant during the forecast period.
Based on geography, the soft tissue sarcoma market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America is anticipated to account for large share of the market during the forecast period. It is likely to be followed by the market in Europe. High incidence rate of soft tissue sarcomas, increase in awareness about soft tissue sarcoma, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.
The soft tissue sarcoma market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by the increase in government spending on healthcare services in India and China. The market in Latin America and Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.
Obtain Report Details @ https://www.transparencymarketresearch.com/soft-tissue-sarcoma-market.html
Key players operating in the soft tissue sarcoma market include Genentech USA, Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb, Hoffmann-La Roche Ltd, Johnson & Johnson, Inc., GlaxoSmithKline, Teva Pharmaceuticals, and Celgene Corporation.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
According to the American Cancer Society, more than 11,400 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. The causes of soft tissue sarcoma are difficult to determine; however, exposure to certain chemicals such as phenoxyacetic herbicides and dioxins; previous exposure to radiotherapy; old age; and certain genetic conditions are anticipated to increase the risk of soft tissue sarcoma. Diagnostic methods used to detect soft tissue sarcoma include PET scan, biopsy, CT scan, and X-ray imaging.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28250
Rise in incidence and prevalence of various types of soft tissue sarcomas, strong focus on research and development to enhance the treatment options available such as targeted therapies and biological therapies, large pipeline of drugs, growth in awareness among people, increase in approvals for the manufacture of generics, and rise in funding for research are some of the factors driving the market.
However, side effects associated with cancer treatment, high cost of treatment, stringent government regulations, and high failure rate in clinical trials are likely to hamper the soft tissue sarcoma market in the near future. Additionally, significant shortage of doxorubicin, one of the major drugs employed in chemotherapy, has been reported by the U.S. FDA. The lack of reimbursement for a majority of the registered drugs under the public insurance programs and the lack of availability of many of the oncology drugs in some of the regions might hamper the future market growth.
The soft tissue sarcoma market can be segmented based on treatment type, end-user, and geography. In terms of the type of treatment, the market can be divided into chemotherapy, targeted therapy, radiation therapy, and surgery. The chemotherapy treatment segment of the soft tissue sarcoma market generally involves a combination of various anti-cancer drugs.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=28250
Commonly used drugs include ifosfamide and doxorubicin. Other chemotherapy drugs include dacarbazine, cisplatin, oxaliplatin, paclitaxel, eribulin, and vincristine. Chemotherapy and targeted therapy segments are anticipated to dominate the soft tissue sarcoma market during the forecast period. In terms of end-user, the soft tissue sarcoma market can be classified into multi-specialty hospitals, cancer research centers, ambulatory surgical centers, and others. Multi-specialty hospitals are anticipated to remain dominant during the forecast period.
Based on geography, the soft tissue sarcoma market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America is anticipated to account for large share of the market during the forecast period. It is likely to be followed by the market in Europe. High incidence rate of soft tissue sarcomas, increase in awareness about soft tissue sarcoma, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.
The soft tissue sarcoma market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by the increase in government spending on healthcare services in India and China. The market in Latin America and Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.
Obtain Report Details @ https://www.transparencymarketresearch.com/soft-tissue-sarcoma-market.html
Key players operating in the soft tissue sarcoma market include Genentech USA, Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb, Hoffmann-La Roche Ltd, Johnson & Johnson, Inc., GlaxoSmithKline, Teva Pharmaceuticals, and Celgene Corporation.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
